CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (661)	12/6/2000 11:59:59 AM
From: Gary L. Kepler	of 666

Perhaps the lack of favorable stock movement for CLTR is because Rituxan has proved to be so effective limiting the potential for follow-on drugs? San Diego Daily Transcript Monday December 04 09:17 PM EST Idec Shows New Rituxan Use San Diego-based Idec Pharmaceuticals presented early Phase III trial data showing its lead drug could be used with chemotherapy to extend the survival time of patients with aggressive non-Hodgkin's lymphoma that had not yet been treated. Interim results for the 400 patient trial showed that with Rituxan, overall year survival rates were extended by 22 percent from chemotherapy alone to 83 percent. In a subset not including the 10 percent group of people with a known reaction to the drug, Rituxan was able to extend survival rates by 39 percent to 68 percent. According to the company, this marks the first new drug combination in 20 years to improve survival in the overall patient population.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next